Tecadenoson is a selective adenosine A1 receptor agonist primarily investigated for use in cardiology to treat heart rhythm disorders, particularly supraventricular tachycardia (SVT). It slows heart rate by reducing electrical conduction in the atrioventricular (AV) node, helping to restore normal rhythm in patients with rapid, irregular heartbeats originating above the ventricles. Its development focuses on providing a targeted alternative to non-selective adenosine agonists, with ongoing exploration in other cardiac conditions requiring heart rate modulation. Use requires medical supervision due to potential side effects.